Research Article

The Histopathology of Labial Salivary Glands in Primary Sjögren’s Syndrome: Focusing on Follicular Helper T Cells in the Inflammatory Infiltrates

Krisztina Szabo,1 Gabor Papp,1 Balazs Dezso,2 and Margit Zeher1

1 Division of Clinical Immunology, Medical Center, University of Debrecen, Moricz Zs. Street 22, Debrecen 4032, Hungary
2 Department of Pathology, Medical Center, University of Debrecen, Nagyerdei Boulevard 98, Debrecen 4032, Hungary

Correspondence should be addressed to Margit Zeher; zeher@iibel.dote.hu

Received 21 May 2014; Revised 11 July 2014; Accepted 11 July 2014; Published 7 August 2014

Academic Editor: Peter Szodoray

Copyright © 2014 Krisztina Szabo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, we revealed the importance of follicular helper T cells (T\text{FH}) in the pathogenesis of primary Sjögren’s syndrome (pSS). In the present study, we focused on the site of the inflammation and determined the composition of lymphocyte infiltration in labial salivary gland (LSG) biopsies with special emphasis on T\text{FH} and germinal center B cells. We selected tissue blocks obtained from ten patients at the time of disease onset. Detection of cell specific markers was performed with immunohistochemical and immunofluorescence stainings. We evaluated patients’ clinical and laboratory features retrospectively and assessed the relation between disease course and early histopathological findings. LSG biopsies were graded based on the extension and arrangement level of periductal inflammatory cell infiltrates. T\text{FH} cell markers (CD84, PD-1, and Bcl-6) occurred predominantly in more organized structures with higher focus scores. The coexpression of CD3 and Bcl-6 markers clearly identified T\text{FH} cells close to Bcl-6\textsuperscript{+} B cells with the typical formation of germinal centers. Systemic features were developed later in the disease course only in patients with highly structured infiltrates and the presence of T\text{FH} cells. Our observations suggest that the presence of T\text{FH} cells in LSGs at the disease onset may predict a more pronounced clinical course of pSS.

1. Introduction

Primary Sjögren’s syndrome (pSS), also known as autoimmune epithelitis, is a common chronic autoimmune disease characterised by the inflammation of exocrine glands and the clinical signs of xerostomia and keratoconjunctivitis sicca. A combination of environmental, genetic, and possibly hormonal factors leads to the dysregulation of the glandular epithelium, mononuclear cell infiltration, and abnormal lymphocyte activation and proliferation [1, 2]. Aberrant humoral autoimmune responses, B cell hyperactivity, and autoantibody production are the hallmarks of pSS [3–5].

Follicular helper T (T\text{FH}) cells are specialized subsets of effector T cells that provide essential help to antigen specific B cells in the secondary lymphoid organs. T\text{FH} cells are originated from naive CD4\textsuperscript{+} T cells which are activated by dendritic cells (DCs) in the interfollicular or T cell zones [6, 7]. As a result of the initial interaction with DCs, primed CD4\textsuperscript{+} T cells migrate to the border of T and B cell areas and become pre-T\text{FH} cells. This follicular homing process is directed by Bcl-6, which coordinates the downregulation of T cell zone homing C-C chemokine receptor type 7 (CCR7) in parallel with the upregulation of B cell region homing C-X-C chemokine receptor 5 (CXCR5) [8–12]. At the border of T and B cell areas, the interaction between pre-T\text{FH} cells and activated B cells is crucial for both the generation of antibody-producing extrafollicular plasmablasts and the formation of germinal centers (GCs). In order to enter GCs, pre-T\text{FH} cells require mutual signals from activated B cells via CD28-CD86, ICOS-ICOSL, CD40L-CD40, programmed cell death protein-1 (PD-1)-PD-1L, and OX40-OX40L as well as signaling lymphocytic activation molecule (SLAM) family members [13–17]. In GCs, the interplay between T\text{FH} and GC B cells is bidirectional; survival signals, completed with interleukin (IL)-21, are important not only for B cell survival, proliferation, and differentiation but also for the maturation
of $T_{FH}$ cells [18, 19]. The upregulation of Bcl-6 in activated GC B cells supports their survival and extremely high proliferation rate and additionally leads to the activation-induced cytidine deaminase (AID) mediated somatic hypermutation (SHM) in the dark zone of GCs [20]. Through the subsequent stimulation of CD40 by $T_{FH}$ cells, centroblasts differentiate into centrocytes and move to the light zone [21]. Follicular DCs (FDCs) and $T_{FH}$ cells promote the positive selection and possible immunoglobulin class-switch recombination (CSR) of several centrocytes resulting in their differentiation into high-affinity memory B cells and long-lived plasma cells [22].

Recent studies highlighted the role of $T_{FH}$ cells in the pathogenesis of different autoimmune conditions, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, juvenile dermatomyositis, myasthenia gravis, and autoimmune thyroid disorders [23–28]. In our previous work, we demonstrated elevated circulating $T_{FH}$ cell percentages in pSS and revealed the importance of this cell type in the pathogenesis of the disease [29]. Despite the increased research activity in this field, the molecular mechanisms and the function of $T_{FH}$ cells are still not known in detail. In order to extend the current knowledge, in the present study we focused on the site of the inflammation and assessed the composition of lymphocyte infiltration in labial salivary gland (LSG) biopsies with a special emphasis on the presence and potential importance of $T_{FH}$ cells at the time of disease onset.

2. Materials and Methods

2.1. Patients. In the present study, we enrolled ten female patients (mean age ± SD: 57.2 ± 11.4) with pSS, who had been diagnosed and followed up regularly in the outpatient clinic for systemic autoimmune diseases at the Division of Clinical Immunology, University of Debrecen. The diagnosis of pSS was established according to the European-American Consensus Group criteria (AECG) [30]. The diagnosis of the patients was confirmed with positive LSG biopsy at the disease onset. None of them had evidence of malignant lymphoma or showed EGMs at the time of the pathological sampling. Three individuals, who complained of only mild sicca symptoms without fulfilling diagnostic criteria, served as controls for the histological evaluation. All patients underwent extensive clinical and serological examinations during the follow-up. Data were obtained retrospectively from their clinical records and archived biopsy samples to be used in this investigation. The study has been approved by the local Ethics Committees (Debrecen, Hungary) in 2012 (Reference number: IX-R-052/00016-22/2012.). All experiments carried out were in compliance with the Declaration of Helsinki.

2.2. LSG Samples and Conventional Histological Analysis. Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were obtained from the archives of the Department of Pathology, University of Debrecen, which had been previously collected for routine diagnostic purposes in years 2001–2010. Four-$\mu$m thick serial sections of LSG tissue specimens were prepared and stained with haematoxylin-eosin (HE) for conventional histopathological examination. The determination of focus score (FS) was based on the degree of lymphocytic infiltration in the whole biopsy. The focus score was defined as the group of inflammatory cell aggregates containing at least 50 mononuclear cells per 4 mm² of tissue area. It was classified as FS = 0: no lymphocytic infiltration; FS = 1: less than 1 lymphocytic focus per 4 mm²; FS = 2: less than 2 lymphocytic foci per 4 mm²; FS = 3: two or more lymphocytic foci per 4 mm² [31].

2.3. Immunohistochemistry. Immunohistochemical (IHC) staining was performed on serial sections of tissue blocks using standard methods [32]. Briefly, 4-$\mu$m thick FFPE sections were deparaffinized, rehydrated on descending ethanol dilutions, and treated with 3% $H_2O_2$ to block endogenous peroxidase. For antigen retrieval, sections were heated in boiling citrate buffer (pH 6.0) or Tris/EDTA buffer (pH 9.0) for 3 min using a pressure cooker. After cooling, the slides were incubated with primary antibodies for 1 hour at room temperature. The following monoclonal antibodies were (mAb) used in the procedure: CD4, clone IF6 mouse mAb (Novocastra, Leica Biosystems, Nussloch, Germany); CD5, clone 4C7 mouse mAb (Novocastra); CD20, clone L26 mouse mAb (Dako, Glostrup, Denmark); CD84, clone EPR8325 rabbit mAb (Abcam, Cambridge, UK); CD138, clone MI15 mouse mAb (Dako); PD-1, clone NAT mouse mAb (Abcam); Bcl-6, clone PG-B6p mouse mAb (Dako). Biotin-free Envision/HRP (Dako) system as secondary Ab with very intense purple (VIP) peroxidase substrate (Vector Laboratories, Peterborough, UK) was used for detection. The sections were then counterstained with methyl green (Vector Laboratories). The stained tissue samples were digitalized using Pannoramic MIDI digital slide-scanner (3D-Histech Co., Budapest, Hungary) utilizing Zeiss Plan-Apochromat objective (magnification: 20x/0.8 numerical aperture) and Hitachi (HV-F22CL) 3CCD progressive scan color camera (resolution: 0.2325 $\mu$m/pixel). Image analysis was performed by the HistoQuant application of Pannoramic Viewer software 1.15.2. (3D-Histech). If applicable, at least 4 (ranging from 2 to 6) lymphocytic foci were selected randomly in each specimen per patient for analytic measurements and photodocumentation. Field area (FA; overall field area in mm²) and mask area (MA; overall mask area in mm²) were computed by the software. The FA represents the whole
area of the marked infiltrates, while the MA indicates the cell-specific marker positive area. The relative MA (rMA) values were calculated as MA/FA multiplied by 100.

2.4. The Characterization of Periductal Cellular Infiltrates. The organizational levels of each lymphocytic infiltrate were graded by IHC staining of serial sections using CD4 and CD20 cell markers. A small number of distributed perivascular and intraepithelial lymphocytes were graded as (1); mild lymphocytic aggregates without clear organization of separate T and B cell zones were defined as grade (2); more organized lymphoid follicles were classified as grade (3); aggregates with the highest level of arrangement, which displayed distinct T and B cell regions, were graded as (4). The latter organization was also characterised by an extensive FDC network detected with CD21 marker in the center of the lymphoid aggregates, whose pattern corresponded to ectopic GC structures.

2.5. Immunofluorescence Staining. Double immunofluorescence (IF) staining for Bcl-6 in combination with CD3 (clone LN10, mmAb, Novocastra) or CD20 was carried out with sequential immunostaining, as described previously [32]. Sections were prepared and antigens were unmasked as detailed above. After 1-hour treatment with anti-Bcl-6 primary Ab, the slides were incubated using anti-mouse IgG(Fab)2 as secondary Ab coupled to polymer-HRP (Dako), followed by a tetramethylrhodamine- (TMR-) conjugated tyramide reagent of the fluorescent amplification kit (TSR-TMR System, Perkin Elmer Life Science, Boston, MA, USA) to visualize the red nuclear fluorescence. The second layer of the double IF staining was applied with anti-CD3 or anti-CD20 primary Abs plus biotinylated anti-mouse secondary IgG F(ab)2, followed by streptavidin-fluorescein isothiocyanate (FITC). Nuclear counterstaining was made with DAPI (blue fluorescence, Vector Laboratories). Images were obtained using a Zeiss AXIO Imager Z2 microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) equipped with the following objectives: 10x/0.3 NA; 20x/0.5 NA. For transferring and editing images, Isis software (MetaSystems Group Inc., Newton, MA, USA) and Adobe Photoshop CS5 version 12.0 were used.

3. Results

3.1. Systemic Characteristics of the Study Population during the Course of the Disease. The mean age at the time of the diagnosis was 50.80 ± 10.34 and the total duration of follow-up was 7.40 ± 3.10 years. We evaluated their clinical and serological features retrospectively and assessed the relation between laboratory results, disease course, and the early histopathological findings. Data of patients enrolled in the study are detailed in Table 1. We divided patients into two groups based on their FSs. Three patients formed the group of pSS with FS = 2 and 7 patients belonged to the group of pSS with FS = 3. None of the patients had FS < 2. Peripheral T<sub>FH</sub>-like cell percentages were tendentially elevated at the end of follow-up in patients with higher FS at disease onset (mean percentages of pSS with FS = 3 versus controls: 0.86% ± 0.38 versus 0.32% ± 0.12, and pSS with FS = 3 versus pSS with FS = 2: 0.86% ± 0.38 versus 0.33% ± 0.08, resp.). Importantly, systemic features such as polyarthritis (n = 3), Raynaud’s syndrome (n = 2), lymphadenopathy (n = 1) and fibrosis pulmonum (n = 1), and associated diseases including primary biliary cirrhosis (n = 1) or primary sclerosing cholangitis (n = 1) developed later in the disease course only in patients with FS = 3.

3.2. Histological Classification of LSG Biopsies according to Focus Scoring and Grading of the Inflammatory Infiltrates. When studying the morphology of LSG specimens in patients with pSS, we identified different organizational levels of inflammatory mononuclear cell infiltrates. The whole LSG specimen was characterized based on the FS, while the extension and the structural arrangement level of each periductal cellular infiltrate were graded within the biopsy section. As displayed in Figure 1(a), four distinct categories could be identified. In our study, the biopsy samples with FS = 2 consisted of lymphocytic aggregates only graded as 1 or 2. More organized follicles as grade 3 or 4 were exclusively found in pSS with FS = 3. Grade 4 lymphocytic foci exhibited features of GCs within secondary lymphoid organs. Figure 1(b) presents the distributions of the four distinguished levels of cellular arrangement in the two groups of patients. In many cases, biopsy specimens included cellular aggregates of different kinds of grades, particularly in higher organizational levels.

3.3. Immunohistochemical Characterization of Infiltrating Cells according to the Cell-Specific Markers in LSG Biopsies. In the biopsy samples of patients with FS = 2, we observed only a mild or moderate degree of periductal lymphocytic infiltration. In pSS with FS = 3, the infiltrations were extensive and penetrated the ductal epithelia with occasional destruction of the acini. Furthermore, three patients from pSS group with FS = 3 also had ectopic GC formation in LSG samples. Serial immunostainings for the incidence and densities of inflammatory cell-specific markers within the infiltrates of the subgroups are demonstrated in Figure 2. As shown, cell surface markers including CD4, CD5, CD20, CD138, CD84, and PD-1 were found in both groups, albeit in different arrangements and densities.

In the aggregates of pSS group with FS = 2, mainly the T helper cell marker CD4, the pan-T cell and B1 cell marker CD5, and the pan-B cell marker CD20 were detected, while the T<sub>FH</sub>-related markers CD84 and PD-1 were less evident. Cells characterized by the above-mentioned molecules showed scattered distribution within the infiltrates. The CD138<sup>+</sup> plasma cells were dispersed throughout the whole LSG samples and found mostly outside the aggregates.

In pSS group with FS = 3, the distribution of specific cell markers showed a different pattern along with more organized structures. CD4<sup>+</sup> T cells were predominantly localized at the periphery of infiltrates. Cells penetrating the ductal epithelia were also positive for CD4. CD5 were detected mainly in the T cell regions at the periphery of mononuclear
Table 1: The demographic and laboratory characteristics of patients with pSS enrolled in the study.

| No. | Age | Age at diagnosis | SSA/Ro (0.00–10.00 U/mL) | SSB/La (0.00–10.00 U/mL) | IgG (7.00–16.00 g/L) | IgA (0.70–4.00 g/L) | IgM (0.40–2.30 g/L) | Focus score (FS) | SSA/Ro (0.00–10.00 U/mL) | SSB/La (0.00–10.00 U/mL) | IgG (7.00–16.00 g/L) | IgA (0.70–4.00 g/L) | IgM (0.40–2.30 g/L) | Peripheral T\(_{FH}\)-like cells (%) |
|-----|-----|------------------|--------------------------|--------------------------|---------------------|---------------------|---------------------|-------------------|--------------------------|--------------------------|---------------------|---------------------|---------------------|--------------------------|
| 1   | 67  | 58               | 176.5                    | 1175                     | 40.86*              | 6.34*               | 2.31*               | 2                 | 120.8                    | 51.9                     | 6.04                | 2.68                | 0.72                | 0.28                     |
| 2   | 75  | 66               | <10                      | 9.12                     | 1.75                | 1.24                | 2                   | 10.4              | <10                      | 8.10                     | 1.75                | 1.19                | 1.19                | 0.42                     |
| 3   | 49  | 46               | 76.3                     | <10                      | 18.09*              | 1.42                | 2.15                | 2                 | 86.6                     | <10                      | 13.49               | 1.91                | 1.70                | 0.30                     |
| 4   | 47  | 38               | <10                      | 14.57                    | 2.90                | 8.23*               | 3                   | <10               | <10                      | <10                      | 13.26               | 2.54                | 5.84*               | 0.92                     |
| 5   | 63  | 53               | <10                      | 14.41                    | 1.47                | 0.74                | 3                   | <10               | <10                      | <10                      | 9.10                | 1.30                | 0.64                | 0.77                     |
| 6   | 65  | 61               | <10                      | 10.18                    | 1.89                | 1.58                | 3                   | <10               | <10                      | <10                      | 9.64                | 2.18                | 1.65                | 1.11                     |
| 7   | 65  | 57               | 130.0                    | 41.0                     | 19.74*              | 3.20                | 3.98*               | 3                 | 123.2                    | 39.5                     | 14.34               | 3.15                | 2.14                | 0.44                     |
| 8   | 41  | 34               | 126.6                    | 76.1                     | 31.97*              | 5.07*               | 1.01                | 3                 | 146.5                    | 68.6                     | 22.79*              | 2.95                | 0.75                | 1.56                     |
| 9   | 64  | 52               | <10                      | 27.24*                   | 6.31*               | 2.38*               | 3                   | <10               | <10                      | <10                      | 19.97*              | 5.23*               | 3.43*               | 0.57                     |
| 10  | 46  | 43               | 157.4                    | <10                      | 26.92*              | 6.34*               | 2.97*               | 3                 | 157.4                    | <10                      | 26.92*              | 6.34*               | 2.97*               | 0.68                     |

No.: number; T\(_{FH}\): follicular helper T cell; *higher than normal range.
cell infiltrates and only a few cells in the B cell area were positive for it. The CD20+ B cells were principally situated at the central region of lymphoid follicles. Similar to pSS group with FS = 2, CD138+ plasma cells were also displayed as a scattered distribution outside the infiltrates; however, some of them were observed at the border of B cell zone as well. The expression of CD84 cell surface molecule was diffused throughout the inflammatory infiltrate but accumulated at the inner area. In addition, the expression of PD-1 was solely found in the location of CD20+ B cells. Bcl-6+ cells were detected exclusively in pSS with FS = 3. After analysing the pSS group with FS = 3, intragroup variances were discovered; at grade 4 organization level Bcl-6+ cells were clustered in the central region and expressed with higher intensity, while in grade 3 aggregates Bcl-6+ cells were scattered and showed much lower expression (data not shown).

Digitalized slide imaging allowed us to make numerical comparisons for marker expressions between the two groups. 117 slides were digitalized in total, and the studied proteins were analyzed in randomly selected lymphocytic aggregates. The average size of the aggregates in pSS with FS = 3 was larger than those in pSS with FS = 2 [0.3114 mm² (0.095–0.642) versus 0.1927 mm² (0.058–0.566), resp.]. As shown in Figure 3, distribution of the expression of cell-specific molecules varied according to the focus scores of biopsy samples. The expression of markers which participate in the T_{FH}-B cell interaction were tendentially higher in pSS with FS = 3.

3.4. Double Immunofluorescence for the Demonstration of T_{FH}-Related Bcl-6 with Possible T or B Cell Coexpressions in Autoreactive Lymphocytes of LSG Biopsies. The last question of this study was whether Bcl-6 expression was limited to CD20+ B cell infiltrates of LSG or whether it could be demonstrated in CD3+ T cells as well. To prove that CD3+ Bcl-6+ T cells were involved in the formation of GC-like structures in LSG, we stained sections by double IF for Bcl-6 and CD3 or CD20 expressions. Figure 4(a) shows the double labeling of CD3 pan-T cell marker with the transcription factor Bcl-6 in lesional lymphocytes, indicating that a few T cells in the infiltrates were positive for Bcl-6. The coexpression of the two markers clearly identified T_{FH} cells. Bcl-6+ B cells with the typical formation of conventional GCs have also been detected in the central area of the lymphoid follicle demonstrated in Figure 4(b).

4. Discussion

Obtaining LSG biopsy is part of the routine diagnosis procedures in pSS according to the AECG, and it provides an excellent opportunity to reveal the severity of autoimmune inflammatory processes in the early stage of the disease [33, 34]. Previous studies revealed the presence of T and B cells with fewer macrophages and DCs in LSG of pSS patients [35–37]. The distribution of B cells, DCs, and FDCs correlates positively with the severity of inflammation [38]. Additionally, Foxp3+ cells and IL-17 and IL-21-producing cells were also detected in the infiltrates of LSG tissues [39–41]. In a recent study, Kang et al. demonstrated the coexpression of IL-21 and CXCR5 in LSG infiltrates which raised the question about the presence of T_{FH} cells [40]. Maehara et al. focused on infiltrating T lymphocyte subsets and described that the expression of T helper 2 and certain T_{FH}-related molecules was associated with robust lymphocytic accumulation and
ectopic GC formation [42]. Moreover, Gong et al. recently demonstrated the ability of epithelial cells to induce the differentiation of T<sub>FH</sub> cells in salivary glands [43]. However, before our present investigations, T<sub>FH</sub> cells were not studied in glandular lymphocytic infiltrates with different organizational levels.

In our study, we classified LSG specimens according to the severity of inflammatory cell infiltrates not only with focus scoring but also with grading of the lymphoid aggregates. To determine the FS and the grades of aggregates, we examined the entire tissue section. We observed that the biopsy samples contained different grades of mononuclear cell infiltrates, and the periductal lymphoid structures showed a higher level of organization in pSS group with FS = 3 than in pSS group with FS = 2.

Ectopic GC structures with peripheral positioned T cells, centrally localized B cell area, and a reticular pattern of FDC network were only observed in FS = 3 with grade 4 aggregates. When examining the expression of T<sub>FH</sub>-related molecules, such as CD84, PD-1, and Bcl-6 in the infiltrates, we found a pronounced expression in pSS with FS = 3. CD84, which is a member of SLAM family, is responsible for...
for the maintenance of stable T-B conjugates to achieve a complete interaction and helper function by T<sub>FH</sub> cells \[44\]. PD-1 receptor, which regulates the selection and survival of B cells in the GCs, is also an important phenotypic determinant of T<sub>FH</sub> cells \[45\]. Marked Bcl-6 expression was detected only in grade 4 aggregates with the colocalization of B cell zone. In grade 3 infiltrates, its expression was significantly weaker. Bcl-6 expression could not be demonstrated in lower grades of aggregates at all. It is known that Bcl-6 is specially expressed by GC B cells during the centroblast phase and usually, but not consistently, in centrocytes as well \[20\]. According to experimental studies, \textit{BCL6} gene defect resulted
in disturbed GCs formation, with the lack of SHM and CSR, which highlights the role of Bcl-6 in GC responses [46]. Human studies also demonstrated the requirement of Bcl-6 in the establishment of GCs and found that, in contrast with aggregates, only real ectopic GCs express detectable amount of Bcl-6 [47, 48]. For that purpose, we paid a special attention to the presence and localization of TFH and GC B cells in the mononuclear cell infiltration. With double IF staining, we demonstrated that, close to B cell area, a certain subset of infiltrating T cells expressed both CD3 and Bcl-6 markers, which suggests that the presence of TFH cells was adjacent to GC B cells in LSG lesions. However, real GC-like structures with TFH cells were merely found in those lymphoid follicles that belong to pSS group with FS = 3 and showed more severe inflammatory lesions. Our findings are in correlation with a previous study which revealed the presence of AID in lymphocytic aggregates with higher organizational level in pSS patients [49]. AID is expressed in GC B cells undergoing SHM and CSR, following the upregulation of Bcl-6. We summarized the possible role of TFH cells in lymphoid aggregates in the labial salivary glands of pSS patients in a graphical figure (Figure 5).

It is important to emphasize that our investigations were performed on LSG biopsies which were collected at the time of the diagnosis, when only the initial symptoms developed in patients. The retrospective evaluation, of both laboratory and clinical data recorded during the follow-up period, revealed associations between the formation of GCs with the presence of TFH cells in LSGs at disease onset and the development of EGMs and associated diseases during the disease course. Additionally, patients, who have TFH cells in their salivary gland infiltrations already at the time of diagnosis, seem to also have an elevated peripheral TFH cell ratio later in the disease course. It must be considered that the limitation of the present study is related to its small patient sample; thus, the correlations between the local presence of TFH cells and the development of systemic clinical features cannot be justified statistically. Nevertheless, the present findings are in line with our earlier observations that the higher proportions of TFH cells are associated with higher FS in glandular biopsies and the presence of extraglandular manifestations [29].

5. Conclusion

In the present study we demonstrated that TFH cell markers, including CD84, PD-1, and Bcl-6, occur predominantly in more organized inflammatory cell infiltrates developed in LSGs with higher focus scores. Our results indicate that
the presence of \( T_{FH} \) cells in LSGs at the time of disease onset may predict a more pronounced clinical course of pSS; nevertheless, this observation should be confirmed in a larger patient population as well. We expect that the further understanding of molecular and cellular regulation of \( T_{FH} \) cells will provide new potential therapeutic targets in the treatment of pSS patients with systemic manifestations.

**Abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| AID:         | Activation-induced cytidine deaminase |
| Bcl-6:       | B cell lymphoma 6 |
| CCR7:        | C-C chemokine receptor type 7 |
| CSR:         | Class-switch recombination |
| CXCR5:       | C-X-C chemokine receptor 5 |
| DCs:         | Dendritic cells |
| EGMs:        | Extraglandular manifestations |
| FFPE:        | Formalin-fixed, paraffin-embedded |
| FITC:        | Fluorescein isothiocyanate |
| FDCs:        | Follicular dendritic cells |
| FS:          | Focus score |
| GC:          | Germinat center |
| HE:          | Haematoxylin-eosin |
| HEV:         | High endothelial venule |
| ICOS:        | Inducible T cell costimulator |
| IL:          | Interleukin |
| IHC:         | Immunohistochemistry |
| IF:          | Immunofluorescence |
| Ig:          | Immunoglobulin |
| LSG:         | Labial salivary gland |
| PD-1:        | Programmed cell death protein 1 |
| pSS:         | Primary Sjögren’s syndrome |
| SAP:         | Signaling lymphocytic activation molecule-(SLAM-)-associated protein |
| SHM:         | Somatic hypermutation |
| \( T_{FH} \): | T follicular helper |
| TMR:         | Tetramethylrhodamine |

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

Experimental work was performed by the support of the Hungarian National Scientific Research Fund (OTKA Grant no. K101470 to Margit Zeher) and the TÁMOP-4.2.2.A-11/1/KONV-2012-0023 “DEFENSE-NET” project (Margit Zeher). Krisztina Szabo was financially supported by the Apáczai Csere János Scholarship for Postgraduate Students from the European Union and the State of Hungary, cofinanced by the European Social Fund in the framework of TÁMOP 4.2.4.A/2-11-1-2012-0001 “National Excellence Program.” The project was implemented by the New Hungary Development Plan, cofinanced by the European Social Fund and the European Regional Development Fund. The authors thank Maria Besenyei and Katalin Hegyi for their technical assistance.

**References**

[1] M. Zeher, “Sjögren’s syndrome,” in Sjögren’s Syndrome and Associated Disorders, M. Zeher and P. Szodoray, Eds., pp. 1–25, Transworld Research Network, Kerala, India, 2009.

[2] A. Hansen, P. Lipsky, and T. Dörner, “B cells in Sjögren’s syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue,” *Arthritis Research & Therapy*, vol. 9, no. 4, p. 218, 2007.

[3] J. O. Bohnhorst, M. B. Bjørgen, J. E. Thoen, R. Jonsson, J. B. Natvig, and K. M. Thompson, “Abnormal B cell differentiation in primary Sjögren’s syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with serum IgG concentration,” *Clinical Immunology*, vol. 103, no. 1, pp. 79–88, 2002.

[4] H. Nakamura, A. Kawakami, and K. Eguchi, “Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren’s syndrome,” *Translational Research*, vol. 148, no. 6, pp. 281–288, 2006.

[5] L. A. Aqrawi, K. Skarstein, G. Bredholt, J. G. Brun, and K. A. Broksstad, “Autoantigen-specific memory B cells in primary Sjögren’s syndrome,” *Scandinavian Journal of Immunology*, vol. 75, no. 1, pp. 61–68, 2012.

[6] C. S. Ma, S. Suryani, D. T. Avery et al., “Early commitment of naive human CD4+ T cells to the T follicular helper (FH) cell lineage is induced by IL-12,” *Immunology and Cell Biology*, vol. 87, no. 8, pp. 590–600, 2009.

[7] N. Schmitt, R. Morita, L. Bourdery et al., “Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12,” *Immunity*, vol. 31, no. 1, pp. 158–169, 2009.

[8] C. H. Kim, L. S. Rott, I. Clark-Lewis, D. J. Campbell, L. Wu, and E. C. Butcher, “Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells,” *Journal of Experimental Medicine*, vol. 193, no. 12, pp. 1373–1381, 2001.

[9] S. Hardtke, L. Ohl, and R. Förster, “Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help,” *Blood*, vol. 106, no. 6, pp. 1924–1931, 2005.

[10] N. M. Haynes, C. D. C. Allen, R. Lesley, K. M. Ansel, N. Killeen, and J. G. Oyster, “Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1(high) germinal center-associated subpopulation,” *The Journal of Immunology*, vol. 179, no. 8, pp. 5099–5108, 2007.

[11] M. A. Kroenke, D. Eto, M. Locci et al., “Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation,” *The Journal of Immunology*, vol. 188, no. 8, pp. 3734–3744, 2012.

[12] R. I. Nurieva, Y. Chung, G. J. Martinez et al., “Bcl6 mediates the development of T follicular helper cells,” *Science*, vol. 325, no. 5943, pp. 1001–1005, 2009.

[13] R. R. Ramiscal and C. G. Vinuesa, “T-cell subsets in the germinal center,” *Immunological Reviews*, vol. 252, no. 1, pp. 146–155, 2013.

[14] M. Chen, Z. Guo, W. Ju, B. Ryffel, X. He, and S. G. Zheng, “The development and function of follicular helper T cells in immune responses,” *Cellular and Molecular Immunology*, vol. 9, no. 5, pp. 375–379, 2012.

[15] S. Crotty, E. N. Kersh, J. Cannons, P. L. Schwartzberg, and R. Ahmed, “SAP is required for generating long term humoral immunity,” *Nature*, vol. 421, no. 6920, pp. 282–287, 2003.
[16] H. Akiba, K. Takeda, Y. Kojima et al., “The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo,” *The Journal of Immunology*, vol. 175, no. 4, pp. 2340–2348, 2005.

[17] Y. S. Choi, R. Kageyama, D. Eto et al., “ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6,” *Immmunity*, vol. 34, no. 6, pp. 932–946, 2011.

[18] C. S. Ma, E. K. Deenick, M. Batten, and S. G. Tangye, “The origins, function, and regulation of T follicular helper cells,” *Journal of Experimental Medicine*, vol. 209, no. 7, pp. 1241–1253, 2012.

[19] S. Crotty, “Follicular helper CD4 T cells (THF),” *Annual Review of Immunology*, vol. 29, pp. 621–663, 2011.

[20] U. Klein and R. Dalla-Favera, “Germinal centres: role in B-cell physiology and malignancy,” *Nature Reviews Immunology*, vol. 8, no. 1, pp. 22–33, 2008.

[21] N. S. de Silva, G. Simonetti, N. Heise, and U. Klein, “The diverse roles of IRF4 in late germinal center B-cell differentiation,” *Immunological Reviews*, vol. 247, no. 1, pp. 73–92, 2012.

[22] S. G. Tangye, C. S. Ma, R. Brink, and E. K. Deenick, “The good, the bad and the ugly—T<sub>FH</sub> cells in human health and disease,” *Nature Reviews Immunology*, vol. 13, no. 6, pp. 412–426, 2013.

[23] N. Simpson, P. A. Gatenby, A. Wilson et al., “Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 62, no. 1, pp. 234–244, 2010.

[24] J. Ma, C. Zhu, B. Ma et al., “Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis,” *Clinical and Developmental Immunology*, vol. 2012, Article ID 827480, 7 pages, 2012.

[25] C. Zhu, M. Jie, Y. Liu et al., “Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 3, pp. 943–950, 2012.

[26] R. Morita, N. Schmitt, S. Bentebibel et al., “Human blood CXCR5<sup>+</sup>CD4<sup>+</sup> T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion,” *Immmunity*, vol. 34, no. 1, pp. 108–121, 2011.

[27] C. Luo, Y. Li, W. Liu et al., “Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis,” *Journal of Neuroimmunology*, vol. 256, no. 1-2, pp. 55–61, 2013.

[28] X. Li, Z. Wu, J. Ding, Z. Zheng, L. Chen, and P. Zhu, “Role of the frequency of blood CD4<sup>+</sup> CXCR5<sup>+</sup>CCR6<sup>+</sup> T cells in autoimmunity in patients with Sjögren’s syndrome,” *Biochemical and Biophysical Research Communications*, vol. 422, no. 2, pp. 238–244, 2012.

[29] K. Szabo, G. Papp, S. Barath, E. Gyimesi, A. Szanto, and M. Zeher, “Follicular helper T cells may play an important role in the severity of primary Sjögren’s syndrome,” *Clinical Immunology*, vol. 147, no. 2, pp. 95–104, 2013.

[30] C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group,” *Annals of the Rheumatic Diseases*, vol. 61, no. 6, pp. 554–558, 2002.

[31] G. A. Scardina, G. Spanó, F. Carini et al., “Diagnostic evaluation of serial sections of labial salivary gland biopsies in Sjögren’s syndrome,” *Medicina Oral, Patología Oral y Cirugía Bucal*, vol. 12, no. 8, pp. ES65–ES68, 2007.

[32] A. Szabo, K. Bene, P. Gogolák et al., “RLR-mediated production of interferon-β by a human dendritic cell subset and its role in virus-specific immunity,” *Journal of Leukocyte Biology*, vol. 92, pp. 159–169, 2012.

[33] A. Rasmussen, J. Ice, H. Li et al., “Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort,” *Annals of the Rheumatic Diseases*, vol. 73, no. 1, pp. 31–38, 2013.

[34] A. Tavoni, C. Baldini, W. Bencivelli et al., “Minor salivary gland biopsy and Sjögren’s syndrome: comparative analysis of biopsies among different Italian rheumatologic centres,” *Clinical and Experimental Rheumatology*, vol. 30, no. 6, pp. 929–933, 2012.

[35] S. Salomonsson, M. V. Jonsson, K. Skarstein et al., “Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome,” *Arthritis and Rheumatism*, vol. 48, no. 11, pp. 3187–3201, 2003.

[36] A. Larsson, A. Bredberg, G. Henriksson, R. Manthorpe, and A. Sallmyr, “Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjögren’s syndrome and healthy subjects,” *Scandinavian Journal of Immunology*, vol. 61, no. 1, pp. 98–107, 2005.

[37] M. Prochorec-Sobieszek, T. Wagner, M. Loukas, H. Chwalińska-Sadowska, and M. Oleśińska, “Histopathological and immunohistochemical analysis of lymphoid follicles in labial salivary glands in primary and secondary Sjögren’s syndrome,” *Medical Science Monitor*, vol. 10, no. 4, pp. BR115–BR121, 2004.

[38] M. I. Christodoulou, E. K. Kapsogorgou, and H. M. Moutsopoulos, “Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome,” *Journal of Autoimmunity*, vol. 34, no. 4, pp. 400–407, 2010.

[39] M. I. Christodoulou, E. K. Kapsogorgou, N. M. Moutsopoulos, and H. M. Moutsopoulos, “Foxp3+ T-regulatory cells in Sjögren’s syndrome: Correlation with the grade of the autoimmune lesion and certain adverse prognostic factors,” *The American Journal of Pathology*, vol. 173, no. 5, pp. 1389–1398, 2008.

[40] K. Y. Kang, H. Kim, S. Kwok et al., “Impact of interleukin-21 in the pathogenesis of primary Sjögren’s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands,” *Arthritis Research and Therapy*, vol. 13, no. 5, p. R179, 2011.

[41] G. E. Katsifis, S. Rekka, N. M. Moutsopoulos, S. PILlemher, and S. M. Wahl, “Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis,” *American Journal of Pathology*, vol. 175, no. 3, pp. 1167–1177, 2009.

[42] T. Maehara, M. Moriyama, J. Hayashida et al., “Selective localization of T helper subsets in labial salivary glands from primary Sjögren’s syndrome patients,” *Clinical and Experimental Immunology*, vol. 169, no. 2, pp. 89–99, 2012.

[43] Y. Gong, J. Nititham, K. Taylor et al., “Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome,” *Journal of Autoimmunity*, vol. 51, pp. 57–66, 2014.

[44] H. Qi, J. L. Cannons, F. Klauschens, P. L. Schwartzberg, and R. N. Germain, “SAP-controlled T-B cell interactions underlie germinal centre formation,” *Nature*, vol. 455, no. 7234, pp. 764–769, 2008.

[45] K. L. Good-Jacobson, C. G. Szumilas, L. Chen, A. H. Sharpe, M. M. Tomayko, and M. J. Shlomchik, “PD-1 regulates germinal
center B cell survival and the formation and affinity of long-lived plasma cells,” *Nature Immunology*, vol. 11, no. 6, pp. 535–542, 2010.

[46] B. H. Ye, F. Lista, F. Lo Coco et al., “Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma,” *Science*, vol. 262, no. 5134, pp. 747–750, 1993.

[47] T. Guerrier, L. le Pottier, V. Devauchelle, J. Pers, C. Jamin, and P. Youinou, “Role of toll-like receptors in primary Sjögren’s syndrome with a special emphasis on B-cell maturation within exocrine tissues,” *Journal of Autoimmunity*, vol. 39, no. 1-2, pp. 69–76, 2012.

[48] L. L. Pottier, V. Devauchelle, A. Fautrel et al., “Ectopic germinal centers are rare in Sjögren’s syndrome salivary glands and do not exclude autoreactive B cells,” *Journal of Immunology*, vol. 182, no. 6, pp. 3540–3547, 2009.

[49] M. Bombardieri, F. Barone, F. Humby et al., “Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren’s syndrome,” *Journal of Immunology*, vol. 179, no. 7, pp. 4929–4938, 2007.